Phase 2 Study of Belzutifan MK-6482 Oral Treatment for Advanced PheochromocytomaParaganglioma, Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease Tumors, Wild-Type Gastrointestinal Stromal Tumors, or Solid Tumors with HIF-2 Genetic Changes

What this Trial Is About

Researchers are evaluating the safety and effectiveness of belzutifan as a single therapy for people with advanced pheochromocytomaparaganglioma, pancreatic neuroendocrine tumors, von Hippel-Lindau disease-related tumors, advanced wild-type gastrointestinal stromal tumors, or other advanced solid tumors with genetic changes related to hypoxia inducible factor-2 alpha. This phase 2 study focuses on measuring the objective response rate using standardized criteria reviewed by an independent central panel. Participants will receive oral belzutifan at a dose of 120 mg once daily. Treatment continues until the disease progresses or the participant chooses to stop. The study does not include a comparison group and follows a single-group design. The study period can last up to about 5.5 years to assess treatment effects and safety over time. During the study, participants will have regular assessments including imaging scans reviewed centrally to evaluate tumor response. Researchers will track outcomes such as duration of response, time to response, disease control rate, progression-free survival, overall survival, and any adverse events experienced. Safety and treatment tolerability will be monitored throughout the study. Participants are expected to remain in the study for several years to gather long-term data on belzutifans effects.

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)